Professor John Newell-Price MA PhD FRCP

Dr John Newell-Price

Chair of Endocrinology and Honorary Consultant Physician

E Floor
The Medical School
University of Sheffield
Beech Hill Road
Sheffield S10 2RX

Tel: +44 (0)114 215 9018
Fax: +44 (0)114 271 2475
For Admin Assistance please contact +44 (0)114 215 9024

Research Interests

John Newell-Price trained in medicine at the University of Cambridge and then the Royal London Hospital. He did his specialist training in endocrinology at St. Bartholomew's Hospital, London, where he was an MRC Training Fellow from 1995-1998. He was appointed Senior Lecturer and Honorary Consultant Physician at the University of Sheffield in 2000.

The focus of both his clinical and basic research is glucocorticoids. His group has identified important aspects of epigenetic regulation of proopiomelanocortin, the key regulator of the hypothalamic-pituitary-adrenal axis, and now is using this information to design strategies to modify over-expression in conditions of excess hormone secretion, such as Cushing's disease.

The clinical research programme has been investigating means of inhibiting excess ACTH in man and improving cortisol replacement in adrenally insufficient patients. This has led to the testing of Chronocort, a new and modified-release form of hydrocortisone, in Phase I studies, which has proven to replicate the normal circadian rhythm of cortisol.

Other work focuses on the diagnostic and management strategies for patients with Cushing's syndrome, and those also for patients with neuroendocrine tumours.

In the Healthcare Trust, John chairs the Pituitary and Neuroendocrine Tumour Multidisciplinary Teams.

Activities and Distinctions

  • National Committee Membership
    Society for Endocrinology Clinical Subcommittee, 1997-2000.
    Chair of the UK Medical Committee, Pituitary Foundation, UK, 2007.
    UK and Ireland Neuroendocrine Tumour Society, Executive Officer, 2007.
    UK Acromegaly Database Steering Committee, 2005-to date.
  • Editorship
    Associate Editor of Clinical Endocrinology 2001-to date.
    Editorial Board, Clinical Endocrinology, 2001-to date.
    Editorial Board, Journal of Clinical Endocrinology and Metabolism, 2008-2010.
  • Advisory Boards
    NICE Appraisal of Pituitary Disease, 2004-2005.
  • National and International Guidelines
    Task Force Member (one of six) for the American Endocrine Society's Guidelines on the Diagnosis of Cushing's Syndrome.

Representative Publications

  1. Alia Munir A, Choudhary P, Harrison B, Heller S, Newell-Price J. Continuous glucose monitoring in patients with insulinoma. Clin Endocrinol (Oxf). 2007 in press.
  2. Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randeva HS, Stewart PM, Viswanath A. Home administration of lanreotide Autogel((R)) by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2007 Sep 24; [Epub ahead of print]
  3. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf). 2007 Sep 4; [Epub ahead of print]
  4. Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab. 2007 May;92(5):1758-63.
  5. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2006 Jul;65(1):45-50.
  6. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006 May 13;367(9522):1605-17.
  7. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005 Apr;152(4):569-74.
  8. Merza Z, Edwards N, Walters SJ, Newell-Price J, Ross RJ. Patients with chronic pain and abnormal pituitary function require investigation. Lancet. 2003 Jun 28;361(9376):2203-4.
  9. Newell-Price J, Morris DG, Drake WM, Korbonits M, Monson JP, Besser GM, Grossman AB. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome.J Clin Endocrinol Metab. 2002 Apr;87(4):1640-5.
  10. Newell-Price J, King P, Clark AJ. The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol. 2001 Feb;15(2):338-48.

Current Grants

Society for Endocrinology, £120,000, 2005-2008. RNA interference as therapy for models of Cushing's disease and acromegaly.

Sheffield Hospitals' Charitable Trust, £24,995, 2006-2008. RNA interference as therapy for models of Cushing's disease and acromegaly.

European Union, 450,000 Euros (Joint partner). European Register on Cushing's Syndrome, in Framework of Public Health Programme. 2007-2010.